SEC Comment Letter 0000000000-23-003466 to Adaptimmune Therapeutics PLC (ADAP) (CIK 0001621227)
Adaptimmune Therapeutics PLC (ADAP) (CIK 0001621227)
Date: April 6, 2023 · CIK: 0001621227 · Accession: 0000000000-23-003466
AI Filing Summary & Sentiment
File numbers found in text: 333-271145
Letter
United States securities and exchange commission logo April 6, 2023 Adrian Rawcliffe Chief Executive Officer Adaptimmune Therapeutics PLC 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX United Kingdom Re:Adaptimmune Therapeutics PLC Registration Statement on Form S-4 Filed April 5, 2023 File No. 333-271145 Dear Adrian Rawcliffe: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jackie Cohen, Esq.
Show Raw Text
United States securities and exchange commission logo
April 6, 2023
Adrian Rawcliffe
Chief Executive Officer
Adaptimmune Therapeutics PLC
60 Jubilee Avenue, Milton Park
Abingdon, Oxfordshire OX14 4RX
United Kingdom
Re:Adaptimmune Therapeutics PLC
Registration Statement on Form S-4
Filed April 5, 2023
File No. 333-271145
Dear Adrian Rawcliffe:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jackie Cohen, Esq.